News
AEZS
4.926
-2.46%
-0.124
BRIEF-Aeterna Zentaris Reports Q2 Rev Negative $0.2 Mln
BRIEF-Aeterna Zentaris Reports Q2 Rev Negative $0.2 Mln
Reuters · 6d ago
Aeterna Zentaris GAAP EPS of -$0.87, revenue of $0.2M
Aeterna Zentaris press release (<span class="ticker-h...
Seekingalpha · 6d ago
Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights
– Company ended the quarter with $58.2 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (Nasdaq: AEZS) (TSX: AEZS) (“Aet...
GlobeNewswire · 6d ago
CytomX Therapeutics (CTMX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
CytomX Therapeutics (CTMX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/28 14:02
Aeterna slips ~10% after announcing date of reverse stock split
The shares of the commercial-stage biotech Aeterna Zentaris (NASDAQ:AE...
Seekingalpha · 07/19 13:51
Aeterna Zentaris Announces Effective Date of Share Consolidation
TORONTO, ON, July 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that the C...
GlobeNewswire · 07/18 21:06
Aeterna Zentaris Announces Shareholder Approval Of Share Consolidation
Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and
Benzinga · 07/15 20:17
Aeterna Zentaris Gets Shareholder, Board Approvals for Share Consolidation; Shares Sink After Hours
MT Newswires · 07/15 16:35
Aeterna Zentaris Announces Further Adjournment of Shareholder Meeting
TORONTO, ONTARIO, July 06, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic...
GlobeNewswire · 07/06 20:05
Aeterna Zentaris Announces Results of Annual Meeting of Shareholders
- Vote to approve share consolidation adjourned to July 6, 2022 TORONTO, ONTARIO, June 21, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commerci...
GlobeNewswire · 06/21 20:01
21 Stocks Moving in Friday's Pre-Market Session
Gainers Athersys, Inc. (NASDAQ: ATHX) rose 48.5% to $0.4755 in pre-market trading after dropping more than 12% on Thursday.
Benzinga · 06/17 09:51
BRIEF-Aeterna Zentaris Achieves Proof-Of-Concept For The Treatment Of Nmosd With Aim Biologicals Program
reuters.com · 06/13 12:25
Aeterna Zentaris Achieves Proof-of-Concept for the Treatment of NMOSD with AIM Biologicals Program
– Company advancing AIM Biologicals development program as a potential therapeutic treatment option for neuromyelitis optica spectrum disorder ("NMOSD") – Positive results presented at the 13th International Congress on Autoimmunity being held in Athens, G...
GlobeNewswire · 06/13 12:00
Aeterna Zentaris to Present at the JMP Securities Life Sciences Conference
Live video webcast on Wednesday, June 15th at 12:30 PM ET TORONTO, ONTARIO, June 09, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializin...
GlobeNewswire · 06/09 12:00
Here's Why We're Watching Aeterna Zentaris' (TSE:AEZS) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 06/03 10:58
Aeterna Zentaris licensing partner Consilient launches growth hormone deficiency test in Europe
Aeterna Zentaris (NASDAQ:AEZS) said its licensing partner Consilient Health launched Ghryvelin, an oral test for diagnosing growth hormone deficiency in adults, in Europe. The company said Ghryvelin  (macimorelin) was approved in European in 2019, backed
Seekingalpha · 05/25 12:57
Aeterna Zentaris' Licensing Partner, Consilient Health Announces European Launch Of Ghryvelin For Diagnosing Adult Growth Hormone Deficiency
Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and
Benzinga · 05/25 12:08
Aeterna Zentaris’ Licensing Partner, Consilient Health Announces European Launch of Ghryvelin™ (macimorelin) for Diagnosing Adult Growth Hormone Deficiency
TORONTO, ONTARIO, May 25, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic ...
GlobeNewswire · 05/25 12:00
Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference
TORONTO, ONTARIO, May 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic ...
GlobeNewswire · 05/18 12:00
73 Biggest Movers From Yesterday
Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares jumped 65.9% to close at $2.77 on Monday after gaining around 10% on Friday.
Benzinga · 05/17 08:49
More
Webull provides a variety of real-time AEZS stock news. You can receive the latest news about Aeterna Zentaris Inc through multiple platforms. This information may help you make smarter investment decisions.
About AEZS
Aeterna Zentaris Inc. is a specialty biopharmaceutical company, which is engaged in commercializing and developing therapeutics and diagnostic tests. The Company's lead product, Macrilen (macimorelin), is an oral test indicated for the diagnosis of patients with adult growth hormone deficiency (AGHD). Macrilen (macimorelin) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor (GHSR-1a) and has uses in both endocrinology and oncology indications. The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). It is also developing oral prophylactic bacterial vaccines against each of SARS-CoV-2, the virus that causes COVID-19, and Chlamydia Trachomatis. The Company focuses on the commercialization of macimorelin in Asia and the rest of the world.